Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07197645 · ClinicalTrials.gov registry record · Phase 1
Samarium Optimized for Long-lasting Analgesia in Cancerous End-stage Bone Pain
A Phase 1 study of Bone Pain and Metastatic Bone Tumor, sponsored by Telix Pharmaceuticals (Innovations) Pty Limited.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
- 3
- Study locations
NCT07197645: Recruiting Phase 1 study of Bone Pain and Metastatic Bone Tumor, sponsored by Telix Pharmaceuticals (Innovations) Pty Limited.
NCT07197645 is a Phase 1 study of Bone Pain and Metastatic Bone Tumor that is actively recruiting participants, run by Telix Pharmaceuticals (Innovations) Pty Limited. The registered enrollment target is 33 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (45% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07197645, a Phase 1 study of Bone Pain and Metastatic Bone Tumor, is actively recruiting participants, sponsored by Telix Pharmaceuticals (Innovations) Pty Limited.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is an open label, 2-part early phase study designed to evaluate the safety, pharmacokinetics, radiation dosimetry, and preliminary efficacy of TLX090-Tx in patients with painful bone metastases.
Primary Outcome
Incidence and severity of hematologic and non-hematologic toxicities, graded per CTCAE v5.0, assessed through 6 weeks post-dose.
Conditions Studied
Interventions
- DRUG 153Sm-DOTMP
Study Locations (3)
Texas
- Houston Metro Urology - Houston
- Oncology Consultants - Houston
- Excel Diagnostics and Nuclear Oncology Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2025-10-21 |
| Est. Completion | 2027-07-05 |
| Phase | Phase 1 |
What NCT07197645 shows while recruiting
NCT07197645 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (45% lower).
The record links to 3 conditions, with Bone Pain appearing as the primary indexed condition, and to 1 intervention - of which 153Sm-DOTMP is the first listed.
NCT07197645 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT07197645 about?
NCT07197645 is a clinical study titled "Samarium Optimized for Long-lasting Analgesia in Cancerous End-stage Bone Pain". This is an open label, 2-part early phase study designed to evaluate the safety, pharmacokinetics, radiation dosimetry, and preliminary efficacy of TLX090-Tx in patients with painful bone metastases.
What is the current status of trial NCT07197645?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2025-10-21. Estimated completion is 2027-07-05.
What conditions does trial NCT07197645 study?
This clinical trial studies the following conditions: Bone Pain, Metastatic Bone Tumor, Bone Metastases in Subjects With Advanced Cancer.
What interventions are being tested in trial NCT07197645?
The interventions under investigation include: 153Sm-DOTMP (DRUG).
Who is sponsoring clinical trial NCT07197645?
This trial is sponsored by Telix Pharmaceuticals (Innovations) Pty Limited, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07197645 being conducted?
This trial has 3 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bone Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07197645's enrollment target sits among peer trials
33 1280th of 2000 higher than 705 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI